# CD19+Targeted CAR-T Cell Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma

> **NCT04271410** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Chongqing Precision Biotech Co., Ltd** · enrollment: 80 (estimated)

## Conditions studied

- Leukemia
- Lymphoma, Large B-Cell, Diffuse
- Leukemia, B-cell
- Lymphoma, B-Cell
- Leukemia, Lymphocytic, Chronic, B-Cell

## Interventions

- **BIOLOGICAL:** CD19 CAR-T cells

## Key facts

- **NCT ID:** NCT04271410
- **Lead sponsor:** Chongqing Precision Biotech Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-06-01
- **Primary completion:** 2023-12-31
- **Final completion:** 2024-07-01
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2023-04-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04271410

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04271410, "CD19+Targeted CAR-T Cell Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04271410. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*